跳至主要内容
临床试验/CTRI/2012/04/002601
CTRI/2012/04/002601已完成2 期

A Phase II randomized, double blind placebo controlled study to evaluate the efficacy and safety of Under Eye Cream in healthy human volunteers

Sami labs0 个研究点目标入组 30 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Male and female subjects in generally good health.
  • Subjects of skin types III, IV, and V.
  • Subjects age group 18 - 55 years
  • Subjects willing to give a written informed consent and come for a regular follow up.
  • Subject willing to abide by and comply with the study protocol.
  • Subject has not participated in a similar investigation in the past four weeks.
  • Subjects having mild to severe infra orbital melanosis and fine lines.
  • Subjects with no history of glaucoma, any eye infection.
  • Subjects who have not taken any under eye treatments for at least 14 days prior to
  • Subject should be willing to abstain from spa treatments/facials during the study period.
  • Subject is not pregnant (as determined by interview),and she must agree to use an active
  • form of birth control (i.e, stabilized on oral contraceptives, condom and /or spermicidal foam,
  • IUD, implant, or diaphragm ) for the duration of the study.

排除标准

  • Pregnant or nursing female (as determined by interview).
  • A known history or present condition of allergic response to any cosmetic products.
  • Concomitant topical therapy in under eye area that causes hypopigmentation includes Retinoids and Hydroquinone skin peels.
  • Subjects taking concomitant therapy (such as oral anti oxidants, vitamin E) that might interfere with the study results.
  • Subjects with dermatological disorder of face that may interfere with study evaluation.
  • Subjects with history of abnormal intraocular pressure, history of glaucoma and any eye
  • infection during enrolment
  • Concomitant medicines, that cause hyper pigmentation, include Phenothiazines, Anti-malarials (Chloroquine), Phenytoin sodium, cytotoxic drugs, Sulphonamides.
  • Systemic treatment which may modify the cutaneous state on the day of inclusion or in the previous 30 days, including retinoid therapy.
  • Subjects not willing to discontinue other topical anti ageing, anti wrinkle facial products.
  • Hypersensitivity to any component of the tested products.
  • History of intense sun exposure.
  • Chronic illness which may influence the cutaneous state.
  • Subject participating in any other cosmetic or therapeutic trial.
  • Any underlying uncontrolled medical illness including diabetes mellitus, hypertension, liver disease or history of alcoholism, HIV, hepatitis, or any other serious medical illness.
  • Subjects who have undergone filler treatment under the eye within the past three months.

研究者

发起方
Sami labs

相似试验

进行中(未招募)
1 期
A phase II randomized, double-blind placebo controlled, study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HER2-negative breast cancer.neoadjuvant hormone-receptor positive HER2-negative breast cancerMedDRA version: 16.0Level: LLTClassification code 10006204Term: Breast carcinomaSystem Organ Class: 100000004864
EUCTR2013-001862-41-ITovartis Farma S.p.A372
进行中(未招募)
1 期
A phase II randomized, double-blind placebo controlled, study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HER2-negative breast cancer.neoadjuvant hormone-receptor positive HER2-negative breast cancer
EUCTR2013-001862-41-CZovartis Pharma Services AG372
进行中(未招募)
1 期
A phase II randomized, double-blind placebo controlled, study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HER2-negative breast cancer.
EUCTR2013-001862-41-BEovartis Pharma Services AG372
进行中(未招募)
1 期
A phase II randomized, double-blind placebo controlled, study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HER2-negative breast cancer.neoadjuvant hormone-receptor positive HER2-negative breast cancer
EUCTR2013-001862-41-DEovartis Pharma Services AG372
进行中(未招募)
1 期
A phase II randomized, double-blind placebo controlled, study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HER2-negative breast cancer.neoadjuvant hormone-receptor positive HER2-negative breast cancer
EUCTR2013-001862-41-NLovartis Pharma Services AG372
To study the effect of Under Eye Cream in Healthy... | 临床试验